跳至主要内容
临床试验/NCT03881644
NCT03881644已完成不适用

Investigation of PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

Danish Headache Center1 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2018年7月17日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
37
试验地点
1
主要终点
Incidence of migraine

研究概览

简要总结

The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine

详细描述

Pituitary adenylate cyclase-activating peptide-38 (PACAP38) plays a role in migraine pathophysiology. Infusions of PACAP38 can trigger migraine-like attacks in some migraine patients and will induce flushing in all patients. We are investigating whether treatment with sumatriptan has an effect on the PACAP38-induced flushing and on whether headache and migraine is induced.

The purpose of this study is to investigate PACAP38-induced headache and migraine in patients with migraine who have been treated with either sumatriptan or placebo using purpose-developed standardized interview. The study will be conducted with a double-blind, placebo-controlled crossover study design.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosis of migraine, according to IHS criteria
  • weight between 50 - 100 kilograms
  • women in fertile age must not be pregnant and must use adequate contraception

排除标准

  • migraine more than 5 days per month in average over the past year
  • any primary headache other than migraine, apart from tension-type headache which must be less than 5 days per month
  • headache < 48 hours before experimental day
  • migraine < 72 hours before each experimental day
  • daily / frequent use of any medication apart from contraceptive medication
  • use of any drug less than 5 times the half-life of the drug at the time of the experiment
  • women who are pregnant or breast-feeding at the time of the experiment
  • anamnestic or clinical signs of hypertension (systolic blood pressure > 150 mmHg and/or
  • diastolic blood pressure > 100 mmHg) or hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg)
  • anamnestic or clinical signs of mental illness, or abuse of alcohol / drugs
  • patients with glaucoma or prostate hyperplasia
  • anamnestic or clinical symptoms of any sort that the investigating doctor deemed unfit for participating in the study

研究组 & 干预措施

PACAP38 + Imigran

Active Comparator

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins

AND

Imigran infusion (0.4 mg/min) for 10 mins

干预措施: Imigran (Drug)

PACAP38 + Imigran

Active Comparator

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins

AND

Imigran infusion (0.4 mg/min) for 10 mins

干预措施: Pituitary adenylate cyclase-activating peptide-38 (Other)

PACAP38 + Isotonic Saline

Placebo Comparator

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins

AND

Isotonic saline for 10 mins (placebo)

干预措施: Isotonic Saline (Other)

PACAP38 + Isotonic Saline

Placebo Comparator

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins

AND

Isotonic saline for 10 mins (placebo)

干预措施: Pituitary adenylate cyclase-activating peptide-38 (Other)

结局指标

主要结局

Incidence of migraine

时间窗: From 0 to 12 hours after infusion

Incidence of migraine after PACAP38-infusion will be estimated through a standardized interview based on the international headache classification for migraine

Effect of Sumatriptan

时间窗: From 0 to 12 hours after infusion

Severity of PACAP38-induced headache and migraine after pretreatment with sumatriptan in migraine patients measured by numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable")

次要结局

  • Severity of headache(From 0 to 12 hours after infusion)
  • Facial temperature(From 0 to 4 hours after infusion)
  • Superficial temporal artery diameter(From 0 to 4 hours after infusion)
  • Severity of flushing(From 0 to 4 hours after infusion)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nita Katarina Frifelt Wienholtz

Principal Investigator, Medical Doctor, PhD Student

Danish Headache Center

研究点 (1)

Loading locations...

相似试验